News & Events


Alliance Pharma to acquire rights to Vamousse

Alliance Pharma to acquire rights to Vamousse

05 December 2017

Our client Alliance Pharma plc has announced a deal to acquire the worldwide rights to Vamousse head lice treatment from TyraTech Inc. for up to £13 million.

The Vamousse portfolio is comprised of innovative, pesticide-free consumer healthcare products for the prevention and treatment of human head lice. It was launched in the UK and US in 2014. Net sales for 2016 were £4.9 million with a gross profit of £3.4 million.

The purchase by Alliance Pharma, a speciality pharmaceutical company, is expected to complete before 31 December 2017. Alliance Pharma plan to make use of its EU affiliates and extensive distribution network to drive further growth in the Vamousse brand.

Read the full article.

Sam Bailey, partner from our chemical & materials patent team; Michael Foster, senior associate from our trade mark team; and Edward Kelly, legal services paralegal, work with Alliance Pharma on their IP portfolio.